Article Sidebar

Submitted
Oct 14, 2024
Published
Jun 14, 2025
Download
Pdf
Statistic
Read Counter : 7 Download : 10

Downloads

Download data is not yet available.

Main Article Content

Abstract

The estimated number of DR TB patients in Indonesia is increasing. High adverse drug reactions have the potential to affect the success of DR TB patient treatment. Linezolid is one of the drugs in combination with DR TB therapy that has the potential to cause adverse drug reactions in the form of hematological disorders and visual impairment. This study aims to determine the incidence of Linezolid ADRs, including the incidence, severity, and risk factors associated with the occurrence of ADRs. This type of study is observational with a cross-sectional design conducted retrospectively in DR TB patients at the lung clinic of Hospital 'X" and Hospital "Y" in Indonesia. The results of the study showed that the incidence of ADRs suspected of Linezolid that met the criteria was 70 patients out of a total of 215. The most common type of ADRs was hematological disorders at 89%, the rest were visual impairment. The type of regimen and type of ADRs correlate with the severity of ADRs. It is necessary to monitor drug levels in the blood in order to monitor and prevent the potential for more severe ADRs so that therapy can be individualized.

Keywords

Adverse Drug Reactions Linezolid DR TB

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Anna, M. S., Arau, M., Schmaltz, C. A. S., Id, B. B. A., Id, V. C. R., Medicina, C. De, Unifacs, U. S., & Universities, L. (2023). Impact of adverse drug reactions on the outcomes of tuberculosis treatment. Drug Reactions in Anti-TB Therapy, 1–14. https://doi.org/10.1371/journal.pone.0269765
  2. BPOM RI. (2019). FARMAKOVIGILANS (KEAMANAN OBAT) PANDUAN DETEKSI DAN PELAPORAN EFEK SAMPING OBAT UNTUK TENAGA KESEHATAN. Pusat Farmakovigilans/MESO Nasional, Badan Pengawas Obat dan Makanan.
  3. Comín, A., Brandariz-núñez, D., Hernández-corredoira, V., Guarc-prades, E., & García-navarro, B. (2019). Optic neuropathy associated with linezolid: systematic review of cases. Farmacia Hospi Talaria, 43(2), 61–65. https://doi.org/10.7399/fh.11133
  4. F., I. (2019). Efek Samping Regimen Individual Pengobatan Tb Paru Resistan Obat. 108.
  5. Hyun, D., Tae, P., Park, K., Jong, Y. O., & Park, S. (2015). Linezolid induced retinopathy. Documenta Ophthalmologica. https://doi.org/10.1007/s10633-015-9518-6
  6. Junjie Cheng1,*, Yuan Yuan1,*, Jinmeng Li 1, Ruoying Zhang1, Xudong Fan1, Zhirou Xu2, Huirong Lin3, Xinjun Cai1, M. Z. (2024). Therapeutic Drug Monitoring of Linezolid in Drug-Resistant Tuberculosis Patients : Clinical Factors and Hematological Toxicities. Infection and Drug Resistance, 17(June), 2531–2540.
  7. Kemenkes RI. (2016). Peremenkes Nomor 72 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Kementerian Kesehatan Republik Indonesia. https://drive.google.com/file/d/1mIxK7Ym-MB1_-T4Af0ljoFH4svVt9f_f/view?usp=sharing
  8. Kemenkes RI. (2020). Petunjuk Teknis Penatalaksanaan Tuberkulosis Resisten Obat Di Indonesia.
  9. Lan, Z., Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Sarah, K., Brust, J. C. M., Campbell, J. R., Wai, V., Chang, L., Falzon, D., Guglielmetti, L., Isaakidis, P., Kempker, R. R., Kipiani, M., Kuksa, L., Lange, C., Laniado-laborín, R., Nahid, P.,Singla, R. (2021). Drug-associated adverse events in the treatment of multidrugresistant tuberculosis: an individual patient data meta-analysis. 8(4), 383–394. https://doi.org/10.1016/S2213-2600(20)30047-3.Drug-associated
  10. Lin, B., Hu, Y., Xu, P., Xu, T., Chen, C., He, L., Zhou, M., Chen, Z., Zhang, C., Yu, X., Fang, L., Zhu, J., Ji, Y., Lin, Q., Cao, H., Dai, Y., Lu, X., Shi, C., Li, L., … Jiang, S. (2022). Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. https://doi.org/10.3389/fpubh.2022.967311
  11. Mikiashvili, L., Kipiani, M., Schechter, M. C., Avaliani, Z., Kiria, N., Kempker, R. R., & Diseases, L. (2021). Linezolid use for drug-resistant tuberculosis in Georgia: a retrospective cohort study. Int J Tuberc Lung Dis., 24(4), 436–443. https://doi.org/10.5588/ijtld.19.0444.Linezolid
  12. Obat, T. R., & Indonesia, D. I. (2020). Petunjuk teknis. Kemenkes RI. https://tbindonesia.or.id/wp-content/uploads/2021/06/TBRO_Buku-Juknis-Tuberkulosis-2020-Website.pdf
  13. Oehadian, A., Santoso, P., Ph, D., Menzies, D., Sc, M., & Ph, D. (2022). Concise Clinical Review of Hematologic Toxicity of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis : Role of Mitochondria. Tuberculosis and Respiratory Diseases., 3536(85), 111–121. https://doi.org/REVIEW https://doi.org/10.4046/trd.2021.0122
  14. Padmapriyadarsini, C., Solanki, R., Jeyakumar, S. M., Bhatnagar, A., Muthuvijaylaksmi, M., Jeyadeepa, B., Reddy, D., Shah, P., Sridhar, R., Vohra, V., & Bhui, N. K. (2023). Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis. Antibiotics, 12, 714. https://doi.org/10.3390/antibiotics12040714
  15. PDPI. (2021). Tuberkulosis Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Vol. 001. Perhimpunan Dokter Paru Indonesia.
  16. RI, D. P. K. (2022). Petunjuk Teknis Monitoring dan Manajemen Efek Samping Obat secara Aktif (MESO Aktif) pada Pengobatan TBC Resistan Obat di Indonesia. Kementerian Kesehatan RI.
  17. https://drive.google.com/file/d/174TOPw6QccWjl3ScitkMNo2LeKnLGN6r/view?usp=sharing
  18. Sahilu, T., Getachew, M., Melaku, T., & Sheleme, T. (2020). Adverse Drug Events and Contributing Factors Among Hospitalized Adult Patients at Jimma Medical Center , Southwest Ethiopia : A Prospective Observational Study. 93. https://doi.org/10.1016/j.curtheres.2020.100611
  19. Shanshan Wu, Yuelun Zhang, Feng Sun, Mingting Chen, Lin Zhou, Ni Wang, S. Z. (2016). Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis A Systematic Review and Meta-analysis. American Journal of Therapeutics, 23(2), p e521-e530.
  20. https://doi.org/https://doi.org/10.1097/01.mjt.0000433951.09030.5a
  21. Solomon, B., Woldeamanuel, Y., Ajeme, T., Senkoro, M., & Manyazewal, T. (2025). Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis : A 7-year retrospective cohort study in Addis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 39(March), 100515. https://doi.org/10.1016/j.jctube.2025.100515
  22. Sugiyono. (2010). Statistika Untuk Penelitian. Bandung: Alfabeta.
  23. Susilo, R. (2022). Translation and Validation of the Indonesian Version of the Adverse Drug Reaction Severity Level Instruments in Colorectal Cancer Patients. Journal of Multidisciplinary Healthcare, 15(April), 1153–1161. https://doi.org/https://doi.org/10.2147/JMDH.S353325
  24. Susilo, R., Diantini, A., Lukman, K., Perwitasari, D. A., Rohadi, D., Kolorektal, K., & Hidup, K. (2022). Correlation of Severity of Adverse Drug Reaction of Leucovorin Calcium (Folinic Acid), Fluorouracil, and Oxaliplatin Drug with Quality of Life of Colorectal Cancer Patients. Jurnal Farmasi Klinik Indonesia, 11(3), 225–238. https://doi.org/10.15416/ijcp.2022.11.3.225
  25. Wang, Y., Chen, H., Mcneil, E. B., & Lu, X. (2019). Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou , China : A Cross-Sectional Study. Patient Preference and Adherence, 13, 1641–1653. https://doi.org/http://doi.org/10.2147/PPA.S219920
  26. World Health Organization, (WHO). (2020). GLOBAL TUBERCULOSIS REPORT. WHO.
  27. World Health Organization, (WHO). (2022). Global Tuberculosis Report 2022. https://www.ptonline.com/articles/how-to-get-better-mfi-results
  28. Yudisia Ausi, P. S., Sunjaya, D. K., & Barliana, M. I. (2021). Between Curing and Torturing : Burden of Adverse Reaction in Drug-Resistant Tuberculosis Therapy. Patient Preference and Adherence, 15, 2597–2607. https://doi.org/https://doi.org/10.2147/PPA.S333111